Search - tctmd.com

Displaying 221 - 240 of 303

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

TRIUMPH in Print: Triple-Drug Polypill Shines for Fast, Safe Blood Pressure Reduction

Shelley Wood

August 15, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

L.A. McKeown

July 10, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

Michael O'Riordan

March 15, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

L.A. McKeown

January 22, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2018

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

TRIUMPH in Print: Triple-Drug Polypill Shines for Fast, Safe Blood Pressure Reduction

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Alirocumab Price Slashed in Deal With Express Scripts

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Less Aggressive HbA1c Targets Recommended by American College of Physicians

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content